- Home
- BCDA vs OGEN Comparison
BCDA vs OGEN Comparison
Compare BCDA & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- OGEN
- Stock Information
- Founded
- BCDA N/A
- OGEN 1996
- Country
- BCDA United States
- OGEN United States
- Employees
- BCDA N/A
- OGEN N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- BCDA Health Care
- OGEN Health Care
- Exchange
- BCDA Nasdaq
- OGEN Nasdaq
- Market Cap
- BCDA 7.9M
- OGEN 4.5M
- IPO Year
- BCDA N/A
- OGEN N/A
- Fundamental
- Price
- BCDA $2.68
- OGEN $0.34
- Analyst Decision
- BCDA Strong Buy
- OGEN
- Analyst Count
- BCDA 1
- OGEN 0
- Target Price
- BCDA $25.00
- OGEN N/A
- AVG Volume (30 Days)
- BCDA 73.1K
- OGEN 392.1K
- Earning Date
- BCDA 11-06-2024
- OGEN 11-07-2024
- Dividend Yield
- BCDA N/A
- OGEN N/A
- EPS Growth
- BCDA N/A
- OGEN N/A
- EPS
- BCDA N/A
- OGEN N/A
- Revenue
- BCDA $428,000.00
- OGEN $7,466.00
- Revenue This Year
- BCDA $6.92
- OGEN N/A
- Revenue Next Year
- BCDA N/A
- OGEN N/A
- P/E Ratio
- BCDA N/A
- OGEN N/A
- Revenue Growth
- BCDA 0.71
- OGEN N/A
- 52 Week Low
- BCDA $1.96
- OGEN $0.29
- 52 Week High
- BCDA $23.25
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- BCDA 49.01
- OGEN 36.96
- Support Level
- BCDA $2.39
- OGEN $0.29
- Resistance Level
- BCDA $2.90
- OGEN $0.35
- Average True Range (ATR)
- BCDA 0.18
- OGEN 0.04
- MACD
- BCDA -0.00
- OGEN 0.02
- Stochastic Oscillator
- BCDA 53.70
- OGEN 31.19
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.